Drugs / Neoantigen Vaccines
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06344156 | Apr 2024 → Apr 2026 overdue | pancreatic ductal adenocarcinoma | Sichuan University | Recruiting | No outcome recorded |
| Phase 1 | NCT03674073 | Oct 2018 → Oct 2020 | adult hepatocellular carcinoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen Vaccines | “Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines” NCT06344156 ↗ |
| Modality | Vaccine | “neoantigen-based DC vaccines” NCT03674073 ↗ |
| Route | Intravenous | “five intravenous doses of neoantigen vaccines” NCT06344156 ↗ |